Please assess the completion status of the following clinical trial:

Trial Title: A Comparative Study to Assess Efficacy of Intralesional MMR Vaccine and Intralesional Vitamin D3 in Treatment of Warts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinically diagnosed patients who have more than three warts or single wart in difficult to treat sites (periungual, palms and soles)~Exclusion Criteria:~1. Patients not under any systemic or topical treatment of warts for the last four weeks~2. Patients with a past history of an allergic response to MMR or any other vaccine or Vitamin D~3. Patients with current acute febrile illness or any bacterial infection~4. Immunosuppressed patients~5. Pregnant or lactating women~6. Patients having a past history of asthma, allergic skin disorders or convulsions~7. Patients with keloidal tendency~8. Patient refusal for consent~9. Treating physician's decision to give other treatment modality~10. Patients with hypervitaminosis D, muscle weakness, bone pain, altered sensorium

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Measles, Mumps, Rubella vaccine (Type: EXPERIMENTAL): All Group A patients will receive intralesional MMR.
- Vitamin D3 (Type: EXPERIMENTAL): All Group B patients will receive intralesional Vitamin D3

Based on this trial design, predict the completion outcome and termination type (if applicable).